FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033131480> ?p ?o ?g. }

• W2033131480 endingPage "15538" @default.
• W2033131480 startingPage "15530" @default.
• W2033131480 abstract "Phosphatidic acid (PA) has been identified as a bioactive lipid second messenger, yet despite extensive investigation, no cellular target has emerged as a mediator of its described biological effects. In this study, we identify the γ isoform of the human protein phosphatase-1 catalytic subunit (PP1cγ) as a high affinity in vitro target of PA. PA inhibited the enzyme dose-dependently with an IC50 of 15 nm. Mechanistically, PA inhibited the enzyme noncompetitively with the kinetics of a tight binding inhibitor and aKi value of 0.97 ± 0.24 nm. Together, these data describe one of the most potent in vitro effects of PA. To further elucidate the interaction between PA and PP1cγ, structure/function analysis of the lipid was carried out using commercially available and synthetically generated analogs of PA. These studies disclosed that the lipid-protein interaction is dependent on the presence of the lipid phosphate as well as the presence of the fatty acid side chains, because lipids lacking either of these substituents resulted in complete loss of inhibition. However, the specific composition of the fatty acid side chains was not important for inhibition. Using 1-O-hexadecyl,2-oleoyl-PA, it was also shown that the carbonyl group of the sn-1 acyl linkage is not required for the lipid-protein interaction. Finally, using a lipid-protein overlay assay, it was demonstrated that PP1cγ specifically and directly interacts with phosphatidic acid while not significantly binding other phospholipids. These results identify PA as a tight binding and specific inhibitor of PP1, and they raise the hypothesis that PP1cγ may function as a mediator of PA action in cells. They also argue for the existence of a specific high affinity PA-binding domain on the enzyme. Phosphatidic acid (PA) has been identified as a bioactive lipid second messenger, yet despite extensive investigation, no cellular target has emerged as a mediator of its described biological effects. In this study, we identify the γ isoform of the human protein phosphatase-1 catalytic subunit (PP1cγ) as a high affinity in vitro target of PA. PA inhibited the enzyme dose-dependently with an IC50 of 15 nm. Mechanistically, PA inhibited the enzyme noncompetitively with the kinetics of a tight binding inhibitor and aKi value of 0.97 ± 0.24 nm. Together, these data describe one of the most potent in vitro effects of PA. To further elucidate the interaction between PA and PP1cγ, structure/function analysis of the lipid was carried out using commercially available and synthetically generated analogs of PA. These studies disclosed that the lipid-protein interaction is dependent on the presence of the lipid phosphate as well as the presence of the fatty acid side chains, because lipids lacking either of these substituents resulted in complete loss of inhibition. However, the specific composition of the fatty acid side chains was not important for inhibition. Using 1-O-hexadecyl,2-oleoyl-PA, it was also shown that the carbonyl group of the sn-1 acyl linkage is not required for the lipid-protein interaction. Finally, using a lipid-protein overlay assay, it was demonstrated that PP1cγ specifically and directly interacts with phosphatidic acid while not significantly binding other phospholipids. These results identify PA as a tight binding and specific inhibitor of PP1, and they raise the hypothesis that PP1cγ may function as a mediator of PA action in cells. They also argue for the existence of a specific high affinity PA-binding domain on the enzyme. phosphatidic acid protein phosphatase-1 phospholipase D lysophosphatidic acid diacylglycerol phosphatidylcholine myelin basic protein Tris-buffered saline Changes in cellular phosphatidic acid (PA)1 levels have been correlated to specific cellular responses, but few of these responses have been shown to occur at physiologically relevant concentrations of PA. Cellular PA levels are regulated through three major pathways; 1) the acylation of lysophosphatidic acid (LPA) by lysophosphatidic acid acyltransferase, 2) the phosphorylation of diacylglycerol (DAG) by diacylglycerol kinase, and 3) the hydrolysis of choline from phosphatidylcholine (PC) by phospholipase D (PLD). The tight regulation of these pathways results in low basal cellular concentrations of PA that can be rapidly induced upon stimulation of cells with cellular agonists. This paradigm forms the basis of the hypothesis that PA is a lipid second messenger and a key mediator of these pathways. However, PA still remains without a clearly defined cellular target. The most extensively characterized target of PA is the Raf-1 kinase. Ghosh et al. (1Ghosh S. Strum J.C. Sciorra V.A. Daniel L. Bell R.M. J. Biol. Chem. 1996; 271: 8472-8480Abstract Full Text Full Text PDF PubMed Scopus (379) Google Scholar, 2Ghosh S. Bell R.M. Biochem. Soc. Trans. 1997; 25: 561-565Crossref PubMed Scopus (39) Google Scholar, 3Strum J.C. Ghosh S. Bell R.M. Adv. Exp. Med. Biol. 1997; 407: 421-431Crossref PubMed Google Scholar) have demonstrated that PA binds specifically within a 35-amino acid putative binding domain containing two smaller subdomains, consisting of a small basic region and a small hydrophobic region. Furthermore, they demonstrated in cells that PA plays a critical role in the docking of Raf-1 at the plasma membrane upon translocation by treatment with phorbol ester. In addition to Raf-1, other putative targets have been identified including SHP-1, phospholipase Cγ1, p47phox, and an undefined PA-dependent protein kinase (4Frank C. Keilhack H. Opitz F. Zschornig O. Bohmer F.D. Biochemistry. 1999; 38: 11993-12002Crossref PubMed Scopus (99) Google Scholar, 5Jackowski S. Rock C.O. Arch. Biochem. Biophys. 1989; 268: 516-524Crossref PubMed Scopus (66) Google Scholar, 6Waite K.A. Wallin R. Qualliotine-Mann D. McPhail L.C. J. Biol. Chem. 1997; 272: 15569-15578Abstract Full Text Full Text PDF PubMed Scopus (130) Google Scholar, 7McPhail L.C. Waite K.A. Regier D.S. Nixon J.B. Qualliotine-Mann D. Zhang W.X. Wallin R. Sergeant S. Biochim. Biophys. Acta. 1999; 1439: 277-290Crossref PubMed Scopus (91) Google Scholar). Yet of these potential targets, few have exhibited direct interaction at physiologically relevant concentrations of PA. Protein phosphatase-1 (PP1) is a serine/threonine phosphatase expressed in all eukaryotic cells and has been found to regulate a diverse number of cellular functions including cell cycle regulation, muscle contraction, glycogen metabolism, gene expression, and neurotransmission (8Hubbard M.J. Cohen P. Trends Biochem. Sci. 1993; 18: 172-177Abstract Full Text PDF PubMed Scopus (792) Google Scholar, 9Bollen M. Stalmans W. Crit. Rev. Biochem. Mol. Biol. 1992; 27: 227-281Crossref PubMed Scopus (260) Google Scholar, 10Cohen P.T. Trends Biochem. Sci. 1997; 22: 245-251Abstract Full Text PDF PubMed Scopus (460) Google Scholar). PP1 in cells is found as a holoenzyme consisting of a catalytic subunit (PP1c) and single targeting/regulatory subunit. There are three major isoforms of PP1c: α, β, and γ1, having greater than 90% homology on the protein level. Regulation of phosphatase activity is thought to occur principally through the action of endogenous peptide inhibitors and association with regulatory/targeting subunits (11Watanabe T. Huang H. Horiuchi A. da Cruze Silva E.F. Hsieh-Wilson L. Allen P.B. Shenolikar S. Greengard P. Nairn A.C. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 3080-3085Crossref PubMed Scopus (60) Google Scholar, 12Bollen M. Trends Biochem. Sci. 2001; 26: 426-431Abstract Full Text Full Text PDF PubMed Scopus (255) Google Scholar). It has been suggested that association with specific targeting subunits can regulate PP1 activity by directing its subcellular localization and substrate specificity, thus allowing it to carry out unique functions in the cell. In addition to the regulation by association with a regulatory subunit, PP1 has also been shown to be modulated by lipid mediators as well as direct phosphorylation of the catalytic subunit (13Kishikawa K. Chalfant C.E. Perry D.K. Bielawska A. Hannun Y.A. J. Biol. Chem. 1999; 274: 21335-21341Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar, 14Chalfant C.E. Kishikawa K. Mumby M.C. Kamibayashi C. Bielawska A. Hannun Y.A. J. Biol. Chem. 1999; 274: 20313-20317Abstract Full Text Full Text PDF PubMed Scopus (274) Google Scholar, 15Dohadwala M. da Cruz e Silva E.F. Hall F.L. Williams R.T. Carbonaro-Hall D.A. Nairn A.C. Greengard P. Berndt N. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 6408-6412Crossref PubMed Scopus (228) Google Scholar, 16Liu C.W. Wang R.H. Dohadwala M. Schonthal A.H. Villa-Moruzzi E. Berndt N. J. Biol. Chem. 1999; 274: 29470-29475Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar, 17Wera S. Hemmings B.A. Biochem. J. 1995; 311: 17-29Crossref PubMed Scopus (601) Google Scholar). Previously our group has established that PP1cα is inhibited in vitro by acidic phospholipids at relatively high concentrations (13Kishikawa K. Chalfant C.E. Perry D.K. Bielawska A. Hannun Y.A. J. Biol. Chem. 1999; 274: 21335-21341Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). This inhibition was especially pronounced for PA, which caused complete inhibition at concentrations 10-fold lower than the other phospholipids. In this report, we demonstrate that the γ-isoform of the human PP1 catalytic subunit (PP1cγ) is inhibited by PA with an IC50 of 15 nm, demonstrating high potency. To date, this is one of the most potent in vitro effects of PA observed and may link these two mediators of cellular signal transduction. We therefore set out to describe the mechanism of this inhibition through studying the structure/function relationship mediating the lipid-protein interaction, the biochemical kinetics of PA inhibition, and the direct interaction of PA with PP1cγ. The results from these studies lay the foundation for future investigation of the physiological interaction between PA and PP1cγ. The γ-isoform of the Escherichia coli recombinant human catalytic subunit of PP1 (PP1cγ) was purchased from Calbiochem (La Jolla, CA). Native PP1c was purified from rabbit skeletal muscle and contains a mixture of PP1c isoforms. This preparation was provided to us as a generous gift from Dr. Mathieu Bollen. All lipids were purchased from Avanti Polar Lipids Inc. (Alabaster, AL). Anti-His6 mouse monoclonal antibody was purchased from CLONTECH Laboratories (Palo Alto, CA). Anti-PP1c (E-9) mouse monoclonal antibody was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Goat anti-mouse peroxidase was acquired from Jackson Immunoresearch Laboratories, Inc. (West Grove, PA). The pBAD/His-B E. coli expression vector was purchased from Invitrogen. Restriction enzymes XhoI andKpnI were purchased from Promega (Madison, WI). All other reagents, unless otherwise noted, were purchased from Sigma. Chloroform stocks of the various lipids were stored at −20 °C. An aliquot of the chloroform stock was dried in a glass vial under a stream of nitrogen gas. The dried lipid was resuspended in phosphatase assay buffer (see below) by sonication with a probe tip sonicator (Sonic Dismembrator 550; Fisher) using three 30-s pulses at 8% power. The resulting aqueous suspension was diluted to generate 20× working concentrations, 5 μl of which, was used per reaction. All vesicles were prepared at room temperature. 32P-MBP was labeled as previously described by Kishikawa et al.(13Kishikawa K. Chalfant C.E. Perry D.K. Bielawska A. Hannun Y.A. J. Biol. Chem. 1999; 274: 21335-21341Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar). [32P]Phosphorylase a was prepared according to the manufacturer's instructions, using the protein phosphorylation assay system from Invitrogen. Dephosphorylation of 32P-MBP or [32P]phosphorylase a was carried out in 50 mm Tris-HCl, 20% glycerol (v/v), pH 7.4. Duplicate reactions containing 10.6 microunits of PP1cγ (EC 3.1.3.16) (or an equivalent amount of activity for native PP1c) were preincubated in the presence or absence of lipid vesicles for 10 min at 30 °C. The reactions were then initiated with the addition of32P-labeled substrate and were allowed to proceed for 20 min. The reactions were stopped with the addition of 60% trichloroacetic acid (v/v) to achieve a final concentration of 30% in the reaction mix. To facilitate precipitation of the substrate and enzyme, 250 μg of bovine serum albumin were added as a carrier, and the samples were allowed to incubate on ice for 10 min. Samples were then centrifuged for 5 min at 12,000 × g, and 200 μl of the resulting supernatants were scintillation counted. Scintillation counts were expressed as percentages of the vehicle-treated control. To determine the kinetic mechanism of PA inhibition, phosphatase assays were carried out as above but included the addition of 100 μm MnCl2 to the reaction buffer to stabilize the basal activity and reduce experiment to experiment variation. The activities of substrate dose-response curves were expressed as pmol of Pi/min/ml released. The data were analyzed using the enzyme kinetics module of the Sigma Plot 2001 software package. This module was specially equipped to handle tight binding inhibitor kinetics. 1-Oleoyl,2-stearoyl-PC, dielaidoyl-PC, di-O-octadecyl-PC, and 1-O-hexadecyl,2-oleoyl-PC were converted in vitro to their respective PA analogs for use as inhibitors in the phosphatase assay. Briefly, 5 mg of lipid was dried from a chloroform stock under a stream of nitrogen. It was then resuspended in 2 ml of PLD reaction buffer (200 mm sodium acetate, 80 mm calcium chloride, pH 5.6) by sonication with a probe tip sonicator. One hundred units of cabbage PLD (EC 3.1.4.4) (Sigma) solubilized in PLD reaction buffer was added to the lipid suspension, and the mixture was overlaid with 2 ml of ether. The reaction was allowed to proceed at room temperature and was supplemented with additional enzyme at 2 h increments for 6 h. The reaction was then allowed to proceed overnight at room temperature. The following day, the ether phase was evaporated under a stream of nitrogen, and the aqueous lipid suspension was extracted using the method of Bligh and Dyer (18Bligh E.G. Dyer W.J. Can. J. Biochem. Physiol. 1959; 37: 341-345Crossref Scopus (42861) Google Scholar). The converted lipid was separated from its PC precursor by thin layer chromatography using chloroform:methanol:acetic acid:water (80:15:8:0.5) as the mobile phase. Precursor and product lipids were visualized by staining with iodine and identified based on standards run on adjacent lanes. The converted lipid was scraped and extracted from the silica resin using chloroform:methanol:water (5:5:1). The extracted lipid was then dried down, resuspended in chloroform, and quantitated by measuring lipid phosphate content as previously described (19Ames B.N. Dubin D.T. J. Biol. Chem. 1960; 235: 769-775Abstract Full Text PDF PubMed Google Scholar). The converted, quantitated lipid was then used in phosphatase assays as indicated above. The human PP1cγ sequence was cloned by polymerase chain reaction using the following primers: 5′-CCG CTC GAG CAT GGC GGA TTT AGA TAA ACT C-3′ containing an 5′-XhoI restriction site and 5′-GCG GTA CCC TAT TTC TTT GCT TGC TTT GTG-3′ containing a 3′-KpnI restriction site. The resulting product was restriction digested then ligated into the inducible bacterial expression vector pBAD/His-B, which had been linearized with the same enzymes. The resulting plasmid sequence was verified prior to expression and purification of the recombinant protein. Clones of transformed TOP10 E. coli (Invitrogen) were screened to contain a correct and inducible plasmid. His6-PP1cγ was purified from a 4-liter bacterial culture grown slowly overnight in the presence of 0.0002%l-arabinose to induce expression of the recombinant protein. The bacterial cells were centrifuged for 30 min at 3000 × g, and the pellet was resuspended in 20 mmsodium phosphate, 0.2 m sodium chloride, 20 mmimidazole, 10% glycerol, 0.1 mm phenylmethylsulfonyl fluoride, pH 7.0 (binding buffer). The cells were broken by two passages through a French press, followed by mild sonication with a probe tip sonicator. The total cell lysates were centrifuged at 20,000 × g for 30 min to remove nonsoluble protein, cell debris, and unbroken cells. The total lysate was filtered through a 0.2-μm filter prior to being loaded on the affinity column. All subsequent steps were preformed at 4 °C. The His-tagged protein was captured on metal chelating affinity Sepharose (Amersham Biosciences) prebound with nickel sulfate. The soluble bacterial cell lysate was loaded onto the column at a rate of 0.25 ml/min, and the column was washed extensively with binding buffer followed by an increasing step gradient of imidazole ranging from 50 to 500 mm. When no protein was eluted with 500 mm imidazole, the column was washed with binding buffer containing 0.05 m EDTA. The His6-PP1cγ was recovered from the EDTA fraction and concentrated, and the buffer was exchanged on a PD-10 desalting column (Amersham Biosciences). The protein was then loaded on to a 1-ml MonoQ column (0.5 × 10 cm) in 50 mm Tris-HCl, 1 mm EDTA, 2 mm dithiothreitol, pH 7.4, and eluted with a linear gradient of the same buffer containing 1m NaCl. The peak fractions were identified by activity assays. They were then pooled, and the buffer was exchanged as before. The purified protein was exchanged into 25 mmtriethanolamine HCl, pH 7.5, 200 mm NaCl, 0.1% β-mercaptoethanol, 100 μm EGTA, 0.03% Brij 35, and 25% glycerol. The protein purity was estimated by SDS-PAGE followed by silver staining, and protein content was quantitated with the Pierce BCA protein assay system. The purified recombinant His6-PP1cγ was stored at −70 °C. Lipid-protein overlay assays were performed according to the protocol of Dowler et al.(20Dowler S. Currie R.A. Campbell D.G. Deak M. Kular G. Downes C.P. Alessi D.R. Biochem. J. 2000; 351: 19-31Crossref PubMed Scopus (477) Google Scholar). Equimolar amounts of the indicated lipids were spotted onto Hybond C extra nitrocellulose membrane (Amersham Biosciences) from chloroform stocks. The membranes were allowed to dry under vacuum for 1 h and were then wetted by floating on purified water. The membranes were equilibrated in Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBS-T) for 5 min, followed by blocking with 3% fatty acid free bovine serum albumin/TBS-T (blocking reagent) for 1 h at room temperature. Purified human E. coli recombinant PP1cγ (Calbiochem, >95% purity) or purified recombinant His6-PP1cγ (>90% purity) was diluted into blocking reagent to a final concentration of 0.2 μg/ml. The membranes were then incubated in the presence of the enzyme overnight at 4 °C on a rocking platform. The following day the membranes were washed six times for 5 min with TBS-T. All subsequent steps were carried out at room temperature. The protein was then identified by incubating with a 1:2000 dilution of anti-PP1c or anti-His6 antibody in blocking reagent for 1 h. This was followed by a second wash step of six times for 5 min with TBS-T. Secondary antibody was diluted 1:5000 into blocking reagent and incubated for 1 h. This was followed by a final wash step of twelve times for 5 min with TBS-T. Finally, the protein was visualized using Enhanced Chemiluminescence (Amersham Biosciences) with exposure to Biomax MR film (Eastman Kodak Co.). Because PA has been previously shown to inhibit PP1c, we pursued the mechanism of this inhibition. Initially, the E. coli recombinant catalytic subunit of human PP1γ was incubated in the presence of increasing concentrations of PA. Dose-dependent inhibition of phosphatase activity was observed with an IC50 of 15 nm (Fig. 1A). The control PP1cγ phosphatase activity, in this experiment (similar for all subsequent experiments), was 4.9 ± 1.6 pmol Pi/min/ml released. The inhibition was independent of the substrate used because identical inhibition was observed when using an artificial substrate, 32P-MBP, versus a physiological substrate, [32P]phosphorylase a. Because of reported differences between recombinant and purified preparations of PP1c, we assessed whether PA could inhibit native PP1c (21Alessi D.R. Street A.J. Cohen P. Cohen P.T. Eur. J. Biochem. 1993; 213: 1055-1066Crossref PubMed Scopus (167) Google Scholar, 22Endo S. Connor J.H. Forney B. Zhang L. Ingebritsen T.S. Lee E.Y. Shenolikar S. Biochemistry. 1997; 36: 6986-6992Crossref PubMed Scopus (40) Google Scholar). As demonstrated in Fig. 1B, native PP1c was inhibited by PA with an IC50 of 135 nm. This suggests that PA specifically interacts with a subset of PP1c isoforms contained in the purified preparation. The high degree of potency and specificity of PA for PP1cγ led us to investigate the mechanism of inhibition. To define the biochemical parameters of PA inhibition of PP1cγ, kinetic analysis was performed on substrate dose-response data carried out in the presence and absence of PA. As shown in Fig.2A, PA was able to inhibit PP1cγ activity to the same degree over a wide range of substrate concentrations. However, when the substrate and inhibitor concentrations were maintained in the presence of varying concentrations of enzyme, inhibition of enzyme activity by PA was lost as the enzyme concentration was increased (Fig. 2B). These data suggest that the inhibitor concentration is not in excess of the enzyme concentration, indicating that PA functions as a tight binding inhibitor of PP1cγ. We next performed kinetics analysis using nonlinear least squares regression to determine the kinetics parameters (Fig. 2, C and D). The following equation was used to account for the amount of inhibitor effectively removed from free solution as it bound to the enzyme. v=(v0/(2⋅E))⋅(E-I-Ki+((E-I-Ki)2+4⋅E⋅Ki))Equation 1 where the velocity was calculated in terms ofv0, the initial velocity; E, the initial total enzyme concentration; I, the free inhibitor concentration; and Ki, the inhibition constant.Km and Vmax for MBP were determined to be 7.69 ± 1.22 μm and 37.11 ± 4.37 pmol Pi/min/ml released, respectively. PA inhibited the enzyme noncompetitively (see Fig. 2D), and theKi of PA was determined to be 0.97 ± 0.24 nm. In an attempt to gain a greater understanding of the interaction between PA and PP1cγ, a detailed series of experiments was carried out to identify the critical structural components of PA required for inhibition of PP1cγ. As seen in Fig. 3, there are three major structural features of PA; the phosphate head group (panel I), the lipid side chains (panel II), and the lipid acyl-linkage (panel III). By using commercially available PA or PC analogs (subsequently converted to PA analogs in vitro; indicated by asterisks in Fig. 3), we tested the requirement of these structural features for their contribution toward PP1cγ inhibition. First, the requirement for the phosphate head group was investigated. Inhibition of phosphatase activity was assessed using DAG and monooleoyl-glycerol, both of which lack the phosphate head group. Fig. 4A illustrates that neither DAG nor monooleoyl-glycerol was capable of inhibiting PP1cγ activity, suggesting that the phosphate head group may be required for interaction between the protein and lipid. This was further explored by assessing the effects of the dioleoyl-phosphatidyl-alcohols: phosphatidylmethanol, phosphatidylethanol, and phosphatidylbutanol, on phosphatase activity. We hypothesized that if the phosphate was needed to make a critical contact with amino acids of the enzyme, by placing a methyl group on the phosphate we may be able to inhibit the lipid-protein interaction. Moreover, phosphatidyl-alcohols are formed in cells when phospholipase D is activated in the presence of primary alcohols. Thus, by using a series of phosphatidyl-alcohols, the resulting effects of substituting a hydroxyl group from the phosphomonoester of PA with various alkyl chains from primary alcohols allowed us to assess the significance of the phosphate contact with the enzyme. As can be seen in Fig.4B, when the phosphate of PA has an alkyl substituent, it loses its ability to inhibit PP1cγ. These data imply not only that the presence of the phosphate head group is a requirement but that inhibition of the enzyme is dependent on its direct interaction with critical amino acid residues of PP1cγ. Second, the requirement for the presence of an aliphatic side chain for inhibition of PP1cγ was determined. To this end, analogs that lacked both lipid side chains were evaluated. As seen in Fig.5A, the phosphorylated glycerols, α-glycerophosphate and β-glycerophosphate, were not able to inhibit enzyme activity. This argues that there is a requirement for at least one side chain. To determine whether one side chain is sufficient, we next tested LPA, which mimics PA except that it lacks the sn-2 lipid side chain. LPA was not able to inhibit PP1cγ (Fig. 5B), thus suggesting that both side chains are required for PA to inhibit enzyme activity. Next, the contribution of the length and composition of the lipid side chains toward the inhibition of PP1cγ was explored. Initially, the degree of saturation of the lipid side chains was evaluated to determine the effect on enzyme inhibition. Using the fully saturated PA analogs distearoyl-PA and dioctanoyl-PA, it was observed that neither of the saturated compounds were capable of inhibiting phosphatase activity (Fig. 6A). Interestingly, eliminating the double bond on the lipid side chains abolished inhibitory activity of the lipid, even when the lipid chains were truncated prior to the cis9–10 double bond of PA. These results may indicate that there is a requirement for at least one double bond in the lipid side chains for PA to interact with PP1cγ. However, because these results were somewhat unexpected, we further explored the significance of side chain composition by testing mixed saturated/unsaturated PA analogs. As can be seen in Fig. 6B, 1-stearoyl,2-oleoyl-PA was fully capable of inhibiting PP1cγ phosphatase activity. Furthermore, the use of 1-oleoyl,2-stearoyl-PA was also able to inhibit enzyme activity to the same degree (data not shown). Together these data suggest that there may be a requirement for a single unsaturated side chain; however, there is no specificity for the sn-1 versus the sn-2 position in the structure. To further address the issue of lipid side chain composition, we examined the ability of 1-stearoyl,2-arachidonoyl-PA to inhibit PP1cγ. This compound contains a fully saturated sn-1linked side chain and a polyunsaturated (cis5, 8, 11, 14)sn-2 linked side chain. As can be seen in Fig.6C, this analog was fully capable of inhibiting PP1cγ to the same extent as PA. Similarly, dielaidoyl-PA (diC18:1), containing a [trans9–10] double bond in place of the cis9–10 double bond, also inhibited phosphatase activity to the same extent as dioleoyl-PA (Fig.6D). Together these data support the suggestion that the composition of the lipid side chains is not a major determinant of PP1cγ inhibition. This requirement for at least one double bond in one of the hydrocarbon chains may result from physical conditions such as the solubility of PA and/or the need for vesicle formation and not from differences in interaction with the enzyme. To further evaluate this possibility, we tested a few key compounds for their ability to inhibit PP1cγ when delivered in mixed detergent/lipid micelles. Mixed micelle delivery systems have been used extensively for delivering lipids, which do not easily form vesicles, to soluble enzymes. To explore the possibility that saturated PAs were not forming suitable vesicles, we employed Triton X-100 micelles to deliver dioleoyl-PA, distearoyl-PA, and dioleoyl-DAG to PP1cγin vitro. As shown in Fig. 7, both dioleoyl-PA, and distearoyl-PA were able to inhibit PP1cγ activity, whereas dioleoyl-DAG was not. These data substantiate the notion that lipid side chain composition is not a major determinant of enzyme inhibition by these analogs, while further supporting the evidence that the presence of the phosphate group is crucial for PP1cγ inhibition. Moreover, the mode of lipid delivery to PP1cγ is of critical importance and may indicate a requirement for the presence of a lipid surface to coordinate the lipid-protein interaction. It should be noted that Triton X-100 detergent micelles alone were capable of activating PP1cγ ∼2-fold when delivered as a 0.3% solution. Although the observed activation was dose-dependent, it is believed to be a result of a general sensitivity of the enzyme to hydrophobic compounds, because we observed a similar response with other detergent micelle preparations (data not shown). The last major feature of the PA structure to be investigated was the requirement of the acyl-linkage of the lipid side chains for PP1cγ inhibition. To gain insight as to the significance of the carbonyl group, a mixed alkyl/acyl-PC-derivative was converted to the respective PA analog using cabbage PLD. The converted compound was purified by thin layer chromatography, quantitated, and used to inhibit PP1cγ. As can be seen in Fig. 8, 1-O-hexadecyl,2-oleoyl-PA lacking the carbonyl at thesn-1 position was still capable of potent inhibition of PP1cγ. Unfortunately, the dialkyl-derivative did not serve as a suitable substrate for cabbage PLD and thus could not be converted to its corresponding PA analog. In light of this, these data demonstrate that the sn-1 carbonyl group is not required for PP1cγ inhibition. Given the unavailability of the dialkyl-derivative, we could not determine the contribution of the sn-2carbonyl, if any, in respect to inhibition of PP1cγ. To demonstrate a direct physical interaction between PP1cγ and PA, binding studies were carried out using the lipid-protein overlay method developed by Boss and co-workers (23Stevenson J.M. Perera I.Y. Boss W.F. J. Biol. Chem. 1" @default.
• W2033131480 created "2016-06-24" @default.
• W2033131480 creator A5030359399 @default.
• W2033131480 creator A5090422329 @default.
• W2033131480 date "2002-05-01" @default.
• W2033131480 modified "2023-09-27" @default.
• W2033131480 title "Tight Binding Inhibition of Protein Phosphatase-1 by Phosphatidic Acid" @default.
• W2033131480 cites W1489297798 @default.
• W2033131480 cites W1627099483 @default.
• W2033131480 cites W1633176701 @default.
• W2033131480 cites W1635858559 @default.
• W2033131480 cites W1892570697 @default.
• W2033131480 cites W1965727075 @default.
• W2033131480 cites W1970732641 @default.
• W2033131480 cites W1978071486 @default.
• W2033131480 cites W1989524887 @default.
• W2033131480 cites W1991359253 @default.
• W2033131480 cites W1996334073 @default.
• W2033131480 cites W1998521228 @default.
• W2033131480 cites W2000702475 @default.
• W2033131480 cites W2014413293 @default.
• W2033131480 cites W2027222105 @default.
• W2033131480 cites W2031234701 @default.
• W2033131480 cites W2041518239 @default.
• W2033131480 cites W2043576061 @default.
• W2033131480 cites W2044005459 @default.
• W2033131480 cites W2045987477 @default.
• W2033131480 cites W2067287697 @default.
• W2033131480 cites W2069698030 @default.
• W2033131480 cites W2070214412 @default.
• W2033131480 cites W2079828650 @default.
• W2033131480 cites W2080043307 @default.
• W2033131480 cites W2087095360 @default.
• W2033131480 cites W2141599538 @default.
• W2033131480 cites W2300552860 @default.
• W2033131480 cites W2420458010 @default.
• W2033131480 cites W2429351269 @default.
• W2033131480 cites W4233751197 @default.
• W2033131480 cites W4302171160 @default.
• W2033131480 cites W4376453135 @default.
• W2033131480 doi "https://doi.org/10.1074/jbc.m111555200" @default.
• W2033131480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11856740" @default.
• W2033131480 hasPublicationYear "2002" @default.
• W2033131480 type Work @default.
• W2033131480 sameAs 2033131480 @default.
• W2033131480 citedByCount "82" @default.
• W2033131480 countsByYear W20331314802012 @default.
• W2033131480 countsByYear W20331314802013 @default.
• W2033131480 countsByYear W20331314802014 @default.
• W2033131480 countsByYear W20331314802015 @default.
• W2033131480 countsByYear W20331314802018 @default.
• W2033131480 countsByYear W20331314802019 @default.
• W2033131480 countsByYear W20331314802020 @default.
• W2033131480 crossrefType "journal-article" @default.
• W2033131480 hasAuthorship W2033131480A5030359399 @default.
• W2033131480 hasAuthorship W2033131480A5090422329 @default.
• W2033131480 hasBestOaLocation W20331314801 @default.
• W2033131480 hasConcept C178666793 @default.
• W2033131480 hasConcept C181199279 @default.
• W2033131480 hasConcept C185592680 @default.
• W2033131480 hasConcept C21547065 @default.
• W2033131480 hasConcept C2776909261 @default.
• W2033131480 hasConcept C2778918659 @default.
• W2033131480 hasConcept C2779408958 @default.
• W2033131480 hasConcept C41625074 @default.
• W2033131480 hasConcept C55493867 @default.
• W2033131480 hasConceptScore W2033131480C178666793 @default.
• W2033131480 hasConceptScore W2033131480C181199279 @default.
• W2033131480 hasConceptScore W2033131480C185592680 @default.
• W2033131480 hasConceptScore W2033131480C21547065 @default.
• W2033131480 hasConceptScore W2033131480C2776909261 @default.
• W2033131480 hasConceptScore W2033131480C2778918659 @default.
• W2033131480 hasConceptScore W2033131480C2779408958 @default.
• W2033131480 hasConceptScore W2033131480C41625074 @default.
• W2033131480 hasConceptScore W2033131480C55493867 @default.
• W2033131480 hasIssue "18" @default.
• W2033131480 hasLocation W20331314801 @default.
• W2033131480 hasOpenAccess W2033131480 @default.
• W2033131480 hasPrimaryLocation W20331314801 @default.
• W2033131480 hasRelatedWork W1929831595 @default.
• W2033131480 hasRelatedWork W1973050899 @default.
• W2033131480 hasRelatedWork W1977239731 @default.
• W2033131480 hasRelatedWork W1988275566 @default.
• W2033131480 hasRelatedWork W1996244503 @default.
• W2033131480 hasRelatedWork W2011370461 @default.
• W2033131480 hasRelatedWork W2029835077 @default.
• W2033131480 hasRelatedWork W2094816281 @default.
• W2033131480 hasRelatedWork W2143715951 @default.
• W2033131480 hasRelatedWork W2163803177 @default.
• W2033131480 hasVolume "277" @default.
• W2033131480 isParatext "false" @default.
• W2033131480 isRetracted "false" @default.
• W2033131480 magId "2033131480" @default.
• W2033131480 workType "article" @default.